CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 442 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $44,343 | -2.9% | 821 | 0.0% | 0.00% | -50.0% |
| Q1 2024 | $45,689 | +3739.4% | 821 | +4221.1% | 0.00% | – |
| Q4 2023 | $1,190 | -82.2% | 19 | -87.1% | 0.00% | – |
| Q3 2023 | $6,674 | +642.4% | 147 | +818.8% | 0.00% | – |
| Q2 2023 | $899 | -70.0% | 16 | -60.0% | 0.00% | – |
| Q3 2022 | $3,000 | +50.0% | 40 | 0.0% | 0.00% | – |
| Q2 2022 | $2,000 | 0.0% | 40 | +33.3% | 0.00% | – |
| Q1 2022 | $2,000 | -90.9% | 30 | -89.8% | 0.00% | -100.0% |
| Q4 2021 | $22,000 | -42.1% | 294 | -13.5% | 0.00% | -66.7% |
| Q3 2021 | $38,000 | +442.9% | 340 | +639.1% | 0.00% | +200.0% |
| Q2 2021 | $7,000 | +16.7% | 46 | 0.0% | 0.00% | – |
| Q1 2021 | $6,000 | -25.0% | 46 | -11.5% | 0.00% | -100.0% |
| Q4 2020 | $8,000 | – | 52 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
| Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
| EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
| NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
| ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
| NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
| Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
| Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |